Table of Contents

I. Introduction
   Statement of purpose I-1
   References I-1
   Link to CDC TB references I-2
   Link to on-line NC TB Control Manual I-2
   Contact Information for NC TB Control Medical Director I-2
   Contact information for expert Pediatric TB consultation I-3
   TB Nurse Consultant contact information I-4
   Abbreviations I-4

II. Mantoux Tuberculin Skin Testing (TST) and Interferon Gamma Release Assays (IGRAs)
   TST/IGRA limitations II-1
   Preferred testing table II-1
   TST training II-2
   A. TST Administration II-2
   B. Reading a TST II-3
   C. Interpretation of a TST II-3
   D. False negative TST reactions II-5
   E. False Positive TST reactions II-5
   F. TST Converters II-5
   G. Two-step TST (booster phenomenon) II-6
   H. BCG (Bacille Calmette-Guerin) II-6
   I. Candidates for TST/IGRA and people state supplied PPD can be used for II-6
      1. People legally required to get a TST/IGRA II-7
      2. People that should be tested when initially presenting for care II-7
      3. People on immunosuppressive drugs II-8
      4. Contacts to Children ≤ 2 with a new positive TST/IGRA II-8
      5. Contacts to a pregnant woman with a new positive TST/IGRA II-8
      6. Homeless shelter state and clients II-8
      7. Staff at local jails and detox units II-8
      8. Staff and residents in settings where TST/IGRA is required II-9
   J. Chest X-rays II-9
   K. Two-step TST algorithm II-10
   L. IGRA guidance II-11
   M. Quality Control checklist for administering TST’s II-15
   N. Sample standing order for TST placement II-17
   O. Sample standing order for obtaining IGRA’s II-20

III. Treatment of Latent TB Infection
   A. Overview III-1
   B. Priorities for LTBI treatment III-1
      1. People at highest priority for LTBI treatment III-1
      2. People at medium priority for LTBI treatment III-1
3. People at low priority for LTBI treatment
4. Resource to determine patient’s risk of progression to active TB
5. Positive TST and IGRA’s and determining risk
C. Standards for managing latent TB infection
D. Regimens for Adults > 12 years
   1. Isoniazid and rifapentine for 12 weeks
   2. Rifampin for four months
   3. Isoniazid plus rifampin daily for three months
   4. Isoniazid for 6-9 months
   5. Isoniazid and rifapentine for one month
E. Regimens for infants and children < 12 years
   1. Isoniazid and rifapentine for 12 weeks
   2. Four months of rifampin
   3. Isoniazid and rifampin for 3 months
   4. Isoniazid for 6-9 months
F. Regimen for Pregnant women
   1. Chest X-rays
   2. High risk pregnant women
   3. Low risk pregnant women
   4. Treatment regimens
      a. Rifampin for four months
      b. Isoniazid for six months
G. Pyridoxine
H. Drug doses chart for treating LTBI
I. Monitoring of LTBI Treatment
   1. Isoniazid monitoring
   2. Rifampin monitoring
   3. Isoniazid and Rifapentine monitoring
   4. Reporting adverse reactions to the CDC
J. Hepatotoxicity flowchart
K. Standing order for LTBI
   1. Sample standing order for Rifapentine and Isoniazid
   2. Sample standing order for Rifampin
   3. Sample standing order for Isoniazid

IV. Diagnosis and Treatment of TB Disease
A. Diagnosis and medical evaluation
   1. Medical and social history
   2. TST and IGRA testing
   3. Chest X-ray
   4. Bacteriology
B. Airborne precautions and/or home isolation
C. Diagnostics for suspected TB in children
D. Treatment
1. Standards of TB Disease Management IV-6
2. Regimen for Adults ≥ 12 years with pulmonary TB IV-6
3. Regimen for pregnant women IV-7
4. Regimen for infants and children less than 12 IV-8
5. Regimen for HIV negative non-pregnant adults that are Sputum smear and culture negative pulmonary TB IV-9
6. Regimen for adults with extra-pulmonary TB IV-9
7. Discontinuation of the INH and rifapentine option IV-10
8. Treatment of M. bovis including BCG strain IV-10

E. Drug resistant TB IV-11
F. Pyridoxine when treating active TB IV-13
G. Dosing for adults with reduced renal function IV-13
H. Directly observed therapy IV-14
I. Video Directly observed therapy sample policy IV-15
J. Monitoring during treatment of active TB IV-17
  1. Baseline evaluation IV-18
  2. Follow-up monitoring IV-19
  3. Monitoring chart IV-21
K. TB Drug Adverse Reactions IV-22
  1. Common adverse reactions IV-22
  2. Rash IV-22
  3. Nausea and vomiting & other GI distress IV-23
  4. Hepatotoxicity IV-23
L. Reintroduction of TB Medications for Hepatotoxicity IV-23
M. Flow chart for re-introducing TB medications IV-24
N. Hepatotoxicity flowchart IV-25
O. Reporting TB cases IV-27
P. Death Certificates IV-30
Q. Sample TB treatment agreement IV-31
R. Sample TB treatment agreement in Spanish IV-32
S. TB drug dosages chart IV-33
T. Clinical Pathway for managing tuberculosis suspects/cases IV-34
U. Tool for reporting suspected or confirmed TB cases IV-37
V. Sample standing order for suspected/confirmed TB cases IV-38

V. **TB and HIV/AIDS** V-1
A. Standards of treatment and management V-1
B. LTBI Screening in People living with HIV V-2
C. Candidates for treatment of LTBI V-2
D. Chest X-rays prior to treatment of LTBI V-2
E. LTBI treatment regimens for people with HIV/AIDS V-3
  1. Isoniazid and Rifampin for 12 weeks V-3
  2. Rifampin daily for 4 months V-3
  3. Isoniazid daily for 9 months V-3

NC TB Control Policy Manual (10/2020)
4. Rifabutin daily for 4 months
5. Treatment of LTBI in pregnant women with HIV/AIDS

F. Tuberculosis Disease in people with HIV
   1. Drugs used to treat TB in people with HIV/AIDS > 13
   2. Antiretrovirals and TB drugs
   3. Switching from rifampin to rifabutin before starting
      Anti-retrovirals
   4. Serum drug levels
   5. Taking TB drugs daily versus intermittently
   6. Duration of treatment
   7. Regimens for pregnant women

G. Antiretroviral Therapy

VI. Patient non-adherence
   A. Closure of patient record for non-adherence of treatment of LTBI
   B. Patient non-adherence when treating for active TB disease
      1. Evaluate for barriers
      2. Evaluate for non-adherence during the treatment phase
      3. Defining non-adherence
      4. Isolation orders
         a. Definition of isolation
         b. What an isolation order can do
      5. Compliance order
      6. Intent of isolation and compliance orders
   C. NC Public Health Laws and TB in regard to compliance and isolation
   D. Sample Compliance Order for TB Control
   E. Sample Compliance Order for TB Control in Spanish
   F. Sample Isolation Order to Limit Freedom of Movement
   G. Sample Isolation Order to Limit Freedom of Movement in Spanish
   H. Incarceration procedure
   I. Arrest procedure
   J. Department of Public Safety (DPS) Medical Management
   K. DPS health law violator (HLV) release procedure
   L. NC TB Control (HLV) release letter procedure
   M. Local health department HLV release from prison procedure

VII. TB Drugs
   A. NC TB Program TB drug rules
   B. Local health department pharmacy responsibilities
   C. Information about purified protein derivative (PPD)
   D. Ordering TB drugs and record keeping
   E. Common drug interaction resources
   F. TB drug abbreviations
VIII. Contact Investigation
A. Link to CDC contact investigation guidelines
B. Goals of a contact investigation
C. Prioritization of contacts
D. Case characteristics
E. Contact risk factors
F. Exposure time limits
G. Structuring a contact investigation
   Table 2 Estimating infectious period
   Figure 1. Table on structuring a contact investigation
H. Evaluating the contact
I. Contacts to extra-pulmonary TB
J. Infant born to a household of someone with active pulmonary TB
K. Infant with Hematogenous spread of TB disease
L. Contacts to INH resistant TB disease
M. Contacts to INH and RIF Resistant TB disease (MDR or XDR)
N. Contact investigations in a correctional facility
O. Contact investigation by other health care facilities
P. Documentation of contact investigations

IX. American Lung Association (ALA)
A. ALA incentive funds
B. ALA emergency housing funds
C. ALA emergency utility funds
D. Incentive fund application
E. Emergency housing form A application
F. Emergency housing form B application
G. Emergency utility application
H. W-9 form

X. Selected Resources
A. Charges for services
B. Education and resources
C. New TB Nurse orientation checklist
D. Management of TB suspects/cases in correctional/detention facilities
E. Hurricane/Disaster Action Plan
F. Cohort review
G. Referrals to other states, territories and countries

XI. Infection Control
A. OSHA and CDC guidance
B. Elements of a TB infection control plan
C. Sample health department tuberculosis control policy
D. TB risk assessment - Appendix D from the CDC guidelines
E. TB screening and risk assessment form for newly hired health care personnel X-13

XII. Laboratory Services
A. State Public Health Lab/mycobacteriology
   1. Submitting specimens XI-1
   2. Laboratory results XI-1
   3. Susceptibility testing XI-1
   4. Notification to the health department XI-2
   5. Retention of specimens XI-2
   6. Universal genotyping program XI-2
   7. Private laboratory mycobacteriology XI-2
   8. Nucleic Acid Amplification (NAA) testing XI-2
  10. Sputum induction protocol XI-5
  11. Gastric Aspiration procedure XI-7
  12. Serum concentration levels for TB drugs XI-8
  13. NC State Lab mycobacteriology requisition form link XI-8
  14. Report of positive AFB smear and or culture form link XI-8

XIII. Class A and B Notification of Arrival of Immigrants and Refugees
A. Classifications XIII-1
B. Class A’s XIII-2
C. Assignment of classification XIII-3
D. Creating Class A/B events in NCEDSS XIII-3
E. Process for initial evaluation of class A/B XIII-3
F. Acknowledging the event in NCEDSS XIII-3
G. Documenting the initial evaluation in NCEDSS XIII-3
H. Chest X-rays XIII-3
I. Completing the class A/B TB worksheet wizard in NCEDSS XIII-3
J. Unable to locate class A/B XIII-4
K. Documenting treatment XIII-4
L. Notifying the TB Nurse Consultant- class A/B TB worksheet is complete XIII-4
M. Closing the class A/B event in NCEDSS XIII-4
N. Education and assistance XIII-4
O. Class A/B’s not found in NCEDSS XIII-4
P. Link to information about the overseas examination XIII-4

XIV. TB Related Laws
A. General Statutes XIV-1
   1) 15A-534.5 Detention to Protect Public Health-Pre-trial release XIV-1
   2) 90-21.4 Responsibility, Liability and Immunity of Physicians that report XIV-1
   3) 90-21.5 Minor’s Consent for Certain Medical Health Services XIV-1
4) 90-85.34A Public Health Pharmacy Practice  
5) 115C-323 Employee Health Certificate (Public School Employee)  
6) 130A-25 Misdemeanor (Health Law Violator)  
7) 130A-134 Reportable Diseases and Conditions  
8) 130A-135 Physicians to Report  
9) 130A-136 School Principals and Child Care Operators to Report  
10) 130A-137 Medical Facilities May Report  
11) 130A-139 Persons in Charge of Laboratories to Report  
12) 130A-140 Local Health Directors to Report  
13) 130A-141 Form, Content and Timing of Reports  
14) 130A-141.l Temporary Order to Report  
15) 130A-142 Immunity of Persons Who Report (when necessary to protect public)  
16) 130A-143 Confidentiality of Records  
17) 130A-144 Investigation and Control Measures  
   a. Health Director to investigate reportable diseases  
   b. Records may be released without consent  
   c. Immunity for releasing such records without consent  
   d. Control measures must be given  
   e. Local health department must ensure that control measures are followed  
      and that examination and treatment is given at no cost to the patient  
   f. All persons must comply with control measures  
18) 130A-145 Quarantine and Isolation Authority  
19) 130A-146 Transportation of Bodies with communicable disease  
20) 130A-147 Rules of the Commission for detection, control and prevention  
21) 130A-440 Health assessment for initial school entry  
22) 153A-225 Medical Care of Prisoners  

B. **North Carolina Administrative Code**

Day Care Rules - Health and Other Standards for Center Staff  
1) 10A NCAC 09.0701 Health Standards for Child Care Providers  

Foster Care Rules - Standards for Licensing  
2) 10A NCAC 70E.1104 Criteria for the Family  

Rules for Licensing of Group Homes for the Developmentally Disabled  
3) 10A NCAC 27G.0202 Personnel Requirements  

Rules for the Licensing of Nursing Homes - General Standards of Administration  
4) 10A NCAC 13D.2209 Infection Control  

Rules for Adult Assisted Living Homes, Rest Homes Section .0400 Staff Qualifications
5) 10A NCAC 13F.0406 Test for Tuberculosis XIV-17

Section .0700 - Admission and Discharge

6) 10A NCAC 13F.0703 Tuberculosis Test XIV-17

Licensing of Family Care Homes Staff Qualifications

7) 10A NCAC 13G.0405 Test for Tuberculosis XIV-18
8) 10A NCAC 13G.0907 Respite Care XIV-18

Home Care Rules

9) 10A NCAC 13J.1003 Licensing of Home Care Agencies – Personnel XIV-19

Hospice Rules

10) 10A NCAC 13K.0401 Hospice Licensing Rules – Personnel XIV-21

Jail Rules (Jails, Local Confinement Facilities)

Section .1000 - Health Care of Inmates and Exercise

11) 10A NCAC 14J.1001 Medical Plan XIV-22
12) 10A NCAC 14J.1002 Health Screening Form XIV-22
13) 10A NCAC 14J.1003 Medical Isolation XIV-23

Communicable Disease Rules

Epidemiology Health - Chapter 41, Subchapter 41A - Communicable Disease Control

14) 10A NCAC 41A.0101 Reportable Diseases and Conditions Link XIV-23
15) 10A NCAC 41A.0102 Method Reporting XIV-23
16) 10A NCAC 41A.0103 Duties of Local Health Director: Reporting XIV-25
17) 10A NCAC 41A.0104 Release of Communicable Disease Records for research XIV-26
18) 10A NCAC 41A.0201 Control Measures – General XIV-26
19) 10A NCAC 41A .0202 Control Measures-HIV XIV-28
20) 10A NCAC 41A.0205 Control Measures – Tuberculosis XIV-31
21) 10A NCAC 41A.0206 Infection Control - Health Care Settings XIV-33
22) 10A NCAC 41A.0209 Laboratory Testing- Genotyping XIV-35
23) 10A NCAC 41A.0210 Duties of Attending Physicians XIV-35
24) 10A NCAC 41A.0211 Duties of Other Persons XIV-35
25) 10A NCAC 41A.0907 Release of Information XIV-36
Subchapter 42B - Laboratory Sections

26) 10A NCAC 42B.0105 Microbiology – State Lab to Test for Tuberculosis XIV-36

Public Health Services Standards for Local Health Departments

27) 10A NCAC 46.0201 Mandated Services XIV-37
28) 10A NCAC 46.0214 Communicable Disease Control XIV-37

Pharmacy Rules

29) 21 NCAC 46.2401 Medication in Health Departments XIV-39
30) 21 NCAC 46.2402 Training of Health Department Nurses XIV-39
31) 21 NCAC 46.2403 Drugs and Devices to be Dispensed XIV-40

C. Quick Reference for Tuberculin Skin Testing Requirements

1. Legally Required Tuberculin Skin Testing (TST) XIV-41
2. TST May Be Required by OSHA or Agency Policy XIV-41
3. Other Settings XIV-42

XV. Record Management
A. Local policy and standing orders XV-1
B. Clinical Records and links to TB forms XV-1
C. Obtaining records from other providers XV-2
D. Transferring records XV-3
E. Record retention XV-3